2 results match your criteria: "and the Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Program[Affiliation]"
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
N Engl J Med
January 2019
From Centre Hospitalier Monkole, Kinshasa, Democratic Republic of Congo (L.T.); the Department of Medicine, University Health Network and Mt. Sinai Hospital, and the University of Toronto, Toronto (G.T.); the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Program, Kilifi, Kenya (T.N.W.); the Department of Medicine, Imperial College London, London (T.N.W.); Hospital Pediátrico David Bernardino, Luanda, Angola (B.S.); Mbale Clinical Research Institute and Mbale Regional Referral and Teaching Hospital-Busitema University, Mbale, Uganda (P.O.-O.); the Division of Hematology, Department of Pediatrics, Cincinnati Children's Hospital (A.L., S.E.S., T.S.L., P.T.M., R.E.W.), University of Cincinnati College of Medicine (A.L., P.T.M., R.E.W.), and the Global Health Center, Cincinnati Children's Hospital Medical Center (S.E.S., P.T.M., R.E.W.), Cincinnati; and Cohen Children's Medical Center, New Hyde Park, and the Zucker School of Medicine at Hofstra/Northwell, Hempstead - both in New York (B.A.).
Background: Hydroxyurea is an effective treatment for sickle cell anemia, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in low-resource settings.
Methods: We enrolled children 1 to 10 years of age with sickle cell anemia in four sub-Saharan countries.
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
N Engl J Med
July 2017
From the University of Zimbabwe Clinical Research Center, Harare, Zimbabwe (J.H., M.B.-D., G.M., K.N.); Joint Clinical Research Center, Kampala (V.M., C.K., P.M.), Mbarara (A.L.), and Fort Portal (S. Kabahenda) - all in Uganda; Medical Research Council Clinical Trials Unit at University College London (A.J.S., S.L.P., A.G., M.J.T., A.S.W., D.M.G.), Wellcome Trust Centre for Clinical Tropical Medicine and Department of Paediatrics, Imperial College (K.M.), and Queen Mary University of London (A.J.P.), London, and the Centre for Health Economics, University of York, York (S.W.) - all in the United Kingdom; the Department of Medicine and Malawi-Liverpool-Wellcome Trust Clinical Research Program, Blantyre, Malawi (J.M., S. Kaunda); and Moi University School of Medicine, Eldoret (A.S., M.K.), and the Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Program, Kilifi (C.A., K.M.) - both in Kenya.
Article Synopsis
- In sub-Saharan Africa, about 10% of patients with advanced HIV infection die soon after starting antiretroviral therapy (ART), often due to infections like tuberculosis and cryptococcus.
- A clinical trial in Uganda, Zimbabwe, Malawi, and Kenya involved HIV-infected adults and children starting ART, randomizing participants to receive either enhanced or standard prophylaxis, alongside other treatments, to see how it affected mortality rates after 24 and 48 weeks.
- The results showed that enhanced prophylaxis significantly reduced the mortality rate at 24 weeks (8.9% vs. 12.2%) and continued to show a lower death rate at 48 weeks, indicating better patient outcomes with the enhanced treatment regimen.